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OBJECTIVES The aim of this study was to clarify the serial changes in left ventricular (LV) end-diastolic
pressure (LVEDP) during dynamic exercise in patients with hypertrophic cardiomyopathy
(HCM).
BACKGROUND Although HCM is characterized by impaired resting LV diastolic function, serial changes in
LVEDP during exercise have not been characterized.
METHODS We simultaneously measured LV pressure and LV dimensions during symptom-limited
supine bicycle exercise in 5 healthy individuals and 20 patients with HCM. Exercise
thallium-201 scintigraphic studies were also performed.
RESULTS The LVEDP (baseline: 12 6 5 mm Hg) progressively increased to a maximum value at peak
exercise (28 6 8 mm Hg) in 11 patients with HCM (group I). In the remaining nine patients
with HCM (group II), changes in LVEDP during exercise were biphasic, with an initial
progressive increase and a subsequent gradual decline up to peak exercise (14 6 4 mm Hg at
baseline, 27 6 5 mm Hg at the critical heart rate, 16 6 3 mm Hg at peak exercise).
Exercise-induced changes in LV dimensions and LV peak systolic pressures were similar in
both groups. However, the maximum first derivative of LV pressure was greater and the LV
pressure half-time was shorter in group II than in group I at a similar peak exercise heart rate.
The biphasic changes in LVEDP disappeared by pretreatment with propranolol. The LV
hypertrophy scores were higher in group I than in group II. Exercise thallium-201 images
showed more severe perfusion defects in group I than in group II patients.
CONCLUSIONS The biphasic changes in LVEDP seen during exercise may be related to improved coronary
microcirculation in response to beta-adrenergic stimulation in patients with mild to moderate
HCM. (J Am Coll Cardiol 2001;38:335–43) © 2001 by the American College of
Cardiology
Left ventricular (LV) diastolic dysfunction in patients with
hypertrophic cardiomyopathy (HCM) is characterized by an
increased resistance to diastolic filling associated with im-
paired relaxation, reduced LV compliance and increased
resting LV filling pressures (1). However, LV diastolic
performance, especially in late diastole, during dynamic
exercise has not been fully evaluated in patients with HCM.
Because increases in LV end-diastolic volume are usually
accompanied by increases in LV end-diastolic pressure
(LVEDP), the LVEDP may serve as an index of LV
diastolic function. However, the LVEDP may be elevated
without an increase in LV end-diastolic volume because of
diminished ventricular compliance in the setting of isch-
emia, hypertrophy, fibrosis and infiltrative diseases of the
ventricle and in pericardial disease (2,3). Animal studies
have demonstrated that LVEDP increases markedly during
exercise in the chronically pressure-overloaded hypertro-
phied canine LV (4,5). Serial changes in LVEDP during
dynamic exercise, however, have not been fully characterized
in patients with HCM. The aim of the present study was to
determine the relationship between LVEDP and the inten-
sity of supine bicycle exercise. Therefore, we simultaneously
measured central and systemic hemodynamics by right and
left heart catheterization and LV dimensions by echocardi-
ography during symptom-limited supine bicycle exercise.
METHODS
Study group. We studied 20 patients (mean age: 51 years)
with newly diagnosed nonfamilial, nonobstructive HCM.
All patients had evidence of LV hypertrophy on electrocar-
diograms (ECGs) and echocardiograms. None of the pa-
tients had previously taken cardioactive medications. All
patients were in normal sinus rhythm and had a normal LV
ejection fraction by left ventriculography (mean: 70 6 9%;
range: 55% to 87%). Incidence of HCM was diagnosed
using established clinical, hemodynamic and echocardio-
graphic criteria (6). No significant intraventricular pressure
gradient was detected either at rest or during exercise in any
patient with HCM as assessed by Doppler echocardiogra-
phy. The control group consisted of five patients (mean age:
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57 years) who had been referred for evaluation of atypical
chest pain. All patients in the control group had normal
ECGs, left ventriculograms and echocardiograms. None of
the patients had valvular heart disease or .50% narrowing
of the coronary arteries by coronary arteriography.
The patients with HCM were grouped according to the
changes in the LVEDP in response to dynamic exercise.
Group I consisted of 11 patients in whom the LVEDP
increased progressively with increases in the intensity of
exercise up to peak exercise. Group II consisted of nine
patients in whom the LVEDP changes were biphasic, with
an initial progressive increase (ascending limb) and a sub-
sequent gradual decline (descending limb). We defined the
critical heart rate (HR) as the HR at which the LVEDP
reached a maximal value during progressive increases in
dynamic exercise. The study protocol was approved by our
Institutional Review Committee. Written, informed con-
sent was obtained from all patients.
Simultaneous ECG, echocardiography and catheteriza-
tion. Right and left heart catheterization was performed
using the brachial approach in fasting patients as previously
described (7). An externally balanced and calibrated 6F
pigtail angiographic micromanometer-tipped catheter
(model SPC-464D, Millar Instruments, Houston, Texas)
was used to measure LV pressure. The signal from the
micromanometer was adjusted to match that of the catheter.
A 21-gauge cannula was used to measure the arterial
pressure. The ECGs were recorded using the Mason-Likar
modification of the standard 12-lead ECG. Micromanom-
eter pressure signals and ECGs were recorded simulta-
neously and continuously with a multichannel recorder
(MR-40, TEAC Corp., Tokyo, Japan). Echocardiography
was performed with a Hewlett-Packard (Andover, Massa-
chusetts) model Sonos 2500 ultrasound system equipped
with a 2.5-MHz transducer. The LV pressure, ECG and
phonocardiogram were recorded simultaneously with the
LV short-axis M-mode echocardiogram on a strip chart at
a paper speed of 100 mm/s. Echocardiographic data were
measured and the degree of LV hypertrophy was deter-
mined semiquantitatively as previously described (7).
Hemodynamic study. After baseline data were obtained,
patients performed a symptom-limited supine bicycle er-
gometer exercise test according to a previously described
method (7,8). The initial workload was 25 W (150 kpm/
min) and increased by 25 W every 3 min. We were unable
to obtain clear echocardiographic recordings at workloads
.50 W, probably because of an increase in the air content
of the lungs. Therefore, we analyzed echocardiographic data
during exercise at a workload of 50 W. Representative
recordings of the ECG, LV pressure and the M-mode
echocardiogram in a patient with HCM at baseline and
during 50 W of exercise are illustrated in Figure 1. During
exercise, no patients developed a new outflow tract pressure
gradient or greater than mild mitral regurgitation by Dopp-
ler echocardiography.
Hemodynamic study with propranolol. After the exercise
study had been completed, four of the nine patients with
HCM, who showed biphasic changes in LVEDP during
exercise, were randomly selected to receive an intravenous
injection of propranolol (0.1 to 0.12 mg/kg). Fifteen to
30 min after injection, the exercise protocol was repeated.
Scintigraphic study. Exercise thallium-201 (201Tl) images
were obtained using a single-photon emission computed
tomographic (SPECT) method two days before catheter-
ization. A symptom-limited exercise test was performed
while patients were seated on a bicycle ergometer using the
same exercise protocol as in the hemodynamic study noted
in the preceding text. Thallium-201 (111 MBq) was in-
jected intravenously 1 min before the exercise was stopped.
Stress imaging was performed 10 min after exercise and rest
imaging was performed 3 h later. The 201Tl SPECT images
were obtained with a rotating two-head gamma camera
(ECAM, Toshiba Inc., Tokyo, Japan) equipped with a
low-energy, high-resolution parallel-hole collimator. To-
mographic slices (6 mm thick) were reconstructed for the
vertical long-axis, horizontal long-axis and short-axis.
Determination of plasma catecholamine concentrations.
Blood (5 ml) was collected from the brachial artery at rest
and at peak exercise. Plasma samples (3 ml) were stored at
270°C until the time of assay. The plasma concentrations
of norepinephrine were analyzed by high-performance liq-
uid chromatography.
Hemodynamic data analysis. The LV pressure signals
were digitized at 3-ms intervals and analyzed with software
developed in our laboratory using a 32-bit microcomputer
system (PC-9821-ST20, NEC Corp., Tokyo, Japan). The
LV pressure data at baseline and for four to six points during
exercise with and without propranolol infusion were se-
lected for analysis. We calculated the maximum first deriv-
ative of LV pressure (LV dP/dtmax) as an index of contrac-
tility. To evaluate LV isovolumic relaxation, the pressure
half-time (T1/2) was calculated directly as previously de-
scribed (7).
Scintigraphic analysis. Perfusion was assessed semiquan-
titatively, based on analysis of the apical, midventricular and
basal short-axis, and vertical long-axis tomograms. The LV
Abbreviations and Acronyms
201Tl 5 thallium 201
ANOVA 5 analysis of variance
ECG 5 electrocardiogram
EDD 5 end-diastolic dimension
ESD 5 end-systolic dimension
HCM 5 hypertrophic cardiomyopathy
HR 5 heart rate
LV 5 left ventricular
LV dP/dtmax 5 the maximum first derivative of LV
pressure
LVEDP 5 left ventricular end-diastolic pressure
SPECT 5 single-photon emission computed
tonography
T1/2 5 LV pressure half-time
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myocardium was divided into 20 segments (18 from the
short-axis images and 2 from the vertical long-axis images).
The defect score was defined using a 5-point scale (0 5
normal, 1 5 equivocal, 2 5 mildly reduced perfusion, 3 5
severly reduced perfusion, 4 5 absent perfusion) by two
observers without knowledge of the clinical data (9). The
summed stress score and summed rest score were calculated
as the sum of scores for the 20 segments for the stress and
rest images, respectively. The sum of the differences be-
tween the 20 segments from the stress and rest images was
defined as the summed difference score (10).
Statistical analysis. Results are expressed as the mean 6
SD. One-way factorial analysis of variance (ANOVA) was
used to compare baseline characteristics and hemodynamic
variables at peak exercise between groups. Within-group
comparisons were performed for the hemodynamic changes
during exercise by two-way repeated-measures ANOVA.
When a significant difference was present, intergroup com-
parisons were performed using the Scheffe´ multiple com-
parison test. The relationships between HR, the percent
change for LV dP/dtmax and the percent change for T1/2
were assessed by the nonlinear least-squares fitting tech-
nique. Between-group comparisons of the regression curves
were analyzed by analysis of covariance and the Scheffe´
multiple comparison test. A value of p , 0.05 was consid-
ered statistically significant. The person who analyzed he-
modynamic factors such as T1⁄2 was blinded to the ultimate
group assignment and changes in LVEDP.
RESULTS
No complications occurred with the exercise protocol. The
total exercise time was 546 6 109 s in the control group,
540 6 102 s in group I and 647 6 84 s in group II. No
significant differences occurred in the total exercise time
among the three groups. Baseline characteristics and hemo-
dynamic variables during exercise with and without pro-
pranolol administration are summarized in Tables 1 and 2.
Baseline data. The interventricular septal thickness was
increased in groups I and II, but it was greater in group I
than group II (Table 1). The LV hypertrophy score was
significantly greater in group I than in group II. Under
resting conditions, the LV end-diastolic dimension (EDD)
and end-systolic dimension (ESD) did not differ signifi-
cantly among the three groups (EDD: control, 45.2 6
2.6 mm; group I, 45.9 6 4.6 mm; group II, 45.9 6 3.7 mm.
ESD: control, 25.8 6 4.9 mm; group I, 29.1 6 5.3 mm;
group II, 28.0 6 2.6 mm). The baseline LVEDP was
significantly higher in groups I and II than in the control
Figure 1. Representative electrocardiograms, phonocardiograms, left ventricular pressure (LVP) tracings, and M-mode echocardiograms at baseline and
during 50 W of exercise in a patient with hypertrophic cardiomyopathy.
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group. The baseline T1/2 was significantly longer in groups
I and II than in the control group.
Responses to dynamic exercise. Exercise increased HR to
a similar extent in all three groups (Table 2). Changes in
right atrial pressures and mean arterial pressure, two indi-
cators of changes in preload and afterload, and LV peak
systolic pressure also increased to a similar extent in all three
groups during exercise. In contrast, the evolution of
LVEDP was different in all three groups during exercise. In
the control group, the LVEDP reached a plateau value at a
HR of 80 beats/min. However, in group I, the LVEDP
increased progressively and continuously (Fig. 2). The
absolute increase in LVEDP was significantly greater in
group I than in the control group (16 6 5 mm Hg vs. 8 6
3 mm Hg, respectively). In group II, the changes in
LVEDP showed a biphasic pattern, with an initial increase
(27 6 5 mm Hg) up to the critical HR followed by a
progressive decline back to the baseline value (16 6
3 mm Hg) (Fig. 3). The critical HR ranged from 92 to 106
beats/min (mean: 98 6 4 beats/min). The percent change in
the LV dP/dtmax followed the increase in HR; the increase
in LV dP/dtmax at peak exercise was the greatest in group II
(124 6 48%). The increase in LV dP/dtmax at the critical
HR in group II was much less than that at peak exercise in
group I, whereas the LVEDP was similar. The T1/2
decreased progressively during exercise in all groups (Fig. 4).
However, changes in T1/2 in the control group (236 6
11%) and in group II (228 6 10%) were greater than in
group I (215 6 10%, both, p , 0.05). At 50 W of exercise,
in the control group, neither EDD nor ESD significantly
changed (EDD: from 45.2 6 2.6 to 45.8 6 2.3 mm; ESD:
from 25.8 6 4.9 to 24.2 6 4.6 mm). In contrast, in group
I and in group II, both EDD and ESD decreased signifi-
cantly (group I: EDD: from 45.9 6 4.6 to 42.0 6 4.9 mm,
p , 0.05; ESD: from 29.1 6 5.3 to 26.1 6 6.2 mm, p ,
0.05. Group II: EDD: from 45.9 6 3.7 to 42.9 6 4.3 mm,
p , 0.05; ESD: from 28.0 6 2.6 to 24.3 6 3.0 mm, p ,
0.05).
Responses to exercise after propranolol infusion. At
baseline, after propranolol infusion, the LV peak systolic
pressure and LV dP/dtmax at baseline were significantly
reduced (both p , 0.05), the T1/2 decreased slightly but the
LVEDP was unchanged. During exercise, in group II, the
biphasic pattern of changes in the LVEDP disappeared and
was replaced by a progressive increase up to peak exercise
(Fig. 3); the decrease in T1/2 was attenuated.
Scintigraphic findings. Both HR and systolic arterial pres-
sure at peak exercise were similar in groups I and II during
exercise 201Tl scintigraphy (HR: 137 6 12 vs. 136 6 8
beats/min; systolic arterial pressure: 213 6 32 vs. 205 6
29 mm Hg, respectively). Ten of the 11 patients (91%) in
group I and 4 of the 9 patients (44%) in group II had
abnormal myocardial 201Tl uptake during exercise (p ,
0.01). Furthermore, 10 of the 11 patients (91%) in group I
and 3 of the 9 patients (33%) in group II had reversible
myocardial perfusion defects (p , 0.01). The summed stress
score was significantly greater in group I than in group II
(13.5 6 4.6 vs. 8.3 6 4.0, p , 0.05), whereas the summed
rest score was similar in groups I and II (5.6 6 3.2 vs. 5.3 6
3.1). The summed difference score was significantly greater
in group I than in group II (8.0 6 4.4 vs. 3.0 6 2.2, p ,
0.01). Therefore, patients in group I had more exercise-
induced defects and reversible defects than group II pa-
tients, suggesting a lower ischemic burden in group II.
Changes in plasma catecholamine concentrations. Exer-
cise induced increases in the plasma concentrations of
norepinephrine in all three groups. However, no significant
differences were seen in the plasma concentrations of
norepinephrine at rest (control, 251 6 40 pg/ml; group I,
224 6 115 pg/ml; group II, 237 6 47 pg/ml) or at peak
exercise (control, 926 6 354 pg/ml; group I, 713 6
190 pg/ml; group II, 839 6 263 pg/ml).
Table 1. Baseline Clinical, Echocardiographic, and
Ventriculographic Characteristics of the Patients
Age
(yrs)
IVST
(mm)
PWT
(mm)
LVH
Score
LVEF
(%)
Control Group
1 56 10 10 61
2 68 10 9 78
3 57 11 10 77
4 46 9 9 61
5 59 11 10 57
Mean 57 10 10 67
SD 8 1 1 10
Group I
6 56 20 12 6 62
7 49 18 12 5 73
8 47 22 20 8 60
9 64 18 12 7 72
10 57 26 18 9 87
11 49 20 12 6 78
12 55 18 11 5 55
13 61 15 10 5 81
14 37 15 10 5 70
15 37 28 13 7 74
16 55 25 10 7 77
Mean 52 20* 13* 6 72
SD 9 4 3 1 9
Group II
17 38 19 10 5 59
18 50 15 11 5 63
19 47 17 10 3 62
20 51 16 12 5 73
21 56 16 9 5 71
22 60 17 13 5 65
23 56 15 10 3 71
24 45 16 12 3 71
25 54 18 11 3 85
Mean 51 17*† 11* 4† 69
SD 7 1 1 1 8
*p , 0.05 vs. control group; †p , 0.05 vs. group I.
IVST 5 interventricular septal thickness; LVEF 5 left ventricular (LV) ejection
fraction; LVH 5 LV hypertrophy; PWT 5 posterior wall thickness; SD 5 standard
deviation.
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DISCUSSION
The most novel observation in the present study is that there
were two distinct patterns of exercise-induced changes in
the LVEDP in patients with HCM. The LVEDP steadily
increased throughout exercise in patients with relatively
severe HCM (group I). In contrast, the LVEDP exhibited
biphasic changes in patients with mild to moderate HCM
(group II). Importantly, the LVEDP at peak exercise in
group I was similar to that at the critical HR in group II
patients.
Exercise-induced changes in hemodynamics. The
exercise-induced augmentation of venous return, as re-
flected by changes in mean right atrial pressures, was similar
in groups I and II. In addition, exercise increased the mean
arterial pressure, an indicator of LV afterload, to a similar
extent in groups I and II. Although it was reported that
exercise-induced hypotension occurred in 33% of patients
with HCM (11), abnormal hypotension was not observed in
any subject studied. Furthermore, LVEDP at peak exercise
was lower in group II than group I patients. Therefore, the
prominent increase in LV systolic performance during
exercise in group II cannot be ascribed to changes in LV
loading conditions (i.e., Frank-Staring mechanism), sug-
gesting the augmented LV contractility itself during dy-
namic exercise in group II. Hittinger et al. (12) have
reported that hemodynamic responses to exercise depend
upon the severity of LV hypertrophy. Furthermore, we
observed that the reduction in T1/2 in patients in group II
was greater than in group I patients. The LV functional
reserve during exercise may be preserved in patients with
lesser amounts of LV hypertrophy.
The LVEDP can be elevated without an increase in LV
end-diastolic volume because of diminished ventricular
compliance or alterations in the LV pressure-volume rela-
tionship in the setting of ischemia, hypertrophy, fibrosis and
infiltrative diseases of the ventricle and pericardial disease
(2,3). The fact that LVEDP decreased after critical HR in
group II despite similar LV internal dimensions in both
groups might indicate the substantial improvement of LV
compliance in group II patients.
Myocardial ischemia. Myocardial ischemia plays an im-
portant role in the pathophysiology and natural history of
HCM. Previous studies have demonstrated that myocardial
perfusion defects commonly develop during exercise in
asymptomatic and minimally symptomatic patients with
HCM (13–17). Thallium 201 scintigraphic myocardial
defects in patients with HCM have been repetitively de-
scribed (13–15). Therefore, our data suggest that there was
a lower ischemic burden in group II patients than in group
I patients.
The exact mechanisms responsible for myocardial isch-
emia in HCM are not known. However, an increase in
Figure 2. Relationships between heart rate and DLVEDP (increment from baseline) during dynamic exercise in the control group (left) and group I (right).
Numbers represent the number of patients analyzed. LVEDP 5 left ventricular end-diastolic pressure.
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myocardial oxygen demand beyond the capacity of a vascular
bed that has not grown in proportion to the degree of LV
hypertrophy, abnormal coronary reserve caused by elevated
LV filling pressures, or abnormalities of the small intramu-
ral coronary arteries may be responsible (14–20). Structural
and functional alterations in the intramural coronary arteries
would be expected to be responsible, at least in part, for
myocardial ischemia (18–20), and an abnormal increase in
LVEDP during exercise in group I patients. In contrast,
small intramural coronary artery reserve may not be as
severely impaired in group II patients.
Mechanisms of biphasic LVEDP changes. Udelson et al.
(21) have demonstrated that beta-adrenergic stimulation
with isoproterenol enhances LV relaxation and improves
diastolic pressure-volume relations in HCM compared with
the pacing tachycardia to the same HR. Their results
suggested that the adverse effect of ischemia on LV relax-
ation might be alleviated by beta-adrenergic stimulation in
patients with HCM. Dynamic exercise may have deleterious
effects in patients with severe HCM by increasing HR and
contractility, thereby augmenting myocardial oxygen de-
mand and aggravating myocardial ischemia. However, dy-
namic exercise might also have favorable effects by facilitat-
ing LV relaxation and filling through changes in loading
conditions and coronary vascular tone in patients with mild
HCM.
One of the potential mechanisms of the biphasic LVEDP
changes might be an improved coronary circulation modu-
lated by exercise-induced beta-adrenergic stimulation. The
coronary arteries are richly innervated by beta-adrenergic
nerves, and their activation can exert coronary vasodilation.
However, beta-blockade-induced coronary vasoconstriction
Figure 3. Relationships between heart rate (HR) and DLVEDP (increment from baseline) during dynamic exercise before (filled circle) and after (open
circle) propranolol administration in group II patients. LVEDP 5 left ventricular end-diastolic pressure.
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has been demonstrated to be primarily due to a lower
metabolic demand (22). Neurally and hormonally mediated
vasoconstriction can be overwhelmed by metabolic vasodi-
lation during exercise in normal conscious dogs (23). In the
present study, the exercise-induced biphasic LVEDP
changes in group II patients disappeared after administra-
tion of propranolol. Taken together, beta-adrenergic acti-
vation may play a significant role in the biphasic changes in
LVEDP during dynamic exercise.
Conclusions. Finally, two distinct patterns of exercise-
induced changes in LVEDP can be observed in patients
with HCM. The LVEDP steadily increased throughout
exercise in patients with severe HCM. In contrast, LVEDP
increased initially and then declined during exercise with
concomitant improvement in LV performance in patients
with mild to moderate HCM. The metabolic vasodilation
induced by beta-adrenergic activation might have favorable
effects on LV performance in patients with mild HCM. The
biphasic changes in LVEDP seen during exercise might be
related to improved coronary microcirculation in response to
beta-adrenergic stimulation in patients with mild to mod-
erate HCM.
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